A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD5213 After Oral Administration of Single and Multiple Ascending Doses in Healthy Young and Elderly J
Phase of Trial: Phase I
Latest Information Update: 17 Oct 2015
At a glance
- Drugs AZD 5213 (Primary)
- Indications Alzheimer's disease; Attention-deficit hyperactivity disorder
- Focus Adverse reactions
- Sponsors AstraZeneca
- 27 Oct 2011 Additional location [Japan] identified as reported by ClinicalTrials.gov.
- 24 Oct 2011 Actual initiation date (April 2011) added as reported by ClinicalTrials.gov.
- 24 Oct 2011 Actual end date (Oct 2011) added as reported by ClinicalTrials.gov.